Best Practice & Research Clinical Haematology
Volume 20, Issue 2 , Pages 189-207 , June 2007

Risk assessment in haematopoietic stem cell transplantation: Pre–transplant patient and donor factors: non-HLA genetics

  • Anne M. Dickinson, PhD (Professor)

      Affiliations

    • Corresponding Author InformationTel.: +44 191 222 6794; Fax: +44 191 222 5524.

References 

  1. Bidwell JL, Wood NA, Morse HR, et al. Human cytokine gene nucleotide sequence alignments: supplement 1. European Journal of Immunogenetics. 1999;26:135–223
  2. Bidwell JL, Wood NA, Morse HR, et al. Human cytokine gene nucleotide sequence alignments, 1998. European Journal of Immunogenetics. 1998;25:83–265
  3. Turner D, Grant SC, Yonan N, et al. Cytokine gene polymorphism and heart transplant rejection. Transplantation. 1997;64:776–779
  4. Krenger W, Hill GR, Ferrara JL. Cytokine cascades in acute graft-versus-host disease. Transplantation. 1997;64:553–558
  5. Collin MP, Hart DN, Jackson GH, et al. The fate of human Langerhans cells in hematopoietic stem cell transplantation. The Journal of Experimental Medicine. 2006;203:27–33
  6. Holler E, Ertl B, Hintermeier-Knabe R, et al. Inflammatory reactions induced by pretransplant conditioning–an alternative target for modulation of acute GvHD and complications following allogeneic bone marrow transplantation?. Leukemia & Lymphoma. 1997;25:217–224
  7. Holler E, Kolb HJ, Mittermuller J, et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood. 1995;86:890–899
  8. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011–1016
  9. Dickinson AM, Sviland L, Hamilton PJ, et al. Cytokine involvement in predicting clinical graft-versus-host disease in allogeneic bone marrow transplant recipients. Bone Marrow Transplantation. 1994;13:65–70
  10. Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nature Medicine. 2002;8:410–414
  11. Cullup H, Dickinson AM, Jackson GH, et al. Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants. British Journal of Haematology. 2001;113:807–813
  12. Inohara N, Chamaillard M, McDonald C, Nunez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annual Review of Biochemistry. 2005;74:355–383
  13. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 1992;80:1838–1845
  14. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087–1092
  15. Gratwohl A, Brand R, Apperley J, et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood. 2002;100:3877–3886
  16. Mullighan CG, Bardy PG. Advances in the genomics of allogeneic haemopoietic stem cell transplantation. Drug Development Research. 2004;62:273–292
  17. Abraham LJ, French MA, Dawkins RL. Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha. Clinical and Experimental Immunology. 1993;92:14–18
  18. Pociot F, Briant L, Jongeneel CV, et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. European Journal of Immunology. 1993;23:224–231
  19. Bogunia-Kubik K, Polak M, Lange A. TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation. Bone Marrow Transplantation. 2003;32:617–622
  20. Middleton PG, Taylor PR, Jackson G, et al. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood. 1998;92:3943–3948
  21. Tambur AR, Yaniv I, Stein J, et al. Cytokine gene polymorphism in patients with graft-versus-host disease. Transplantation Proceedings. 2001;33:502–503
  22. Takahashi H, Furukawa T, Hashimoto S, et al. Contribution of TNF-alpha and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2000;26:1317–1323
  23. Wang J, Pan K, Li D, Lu D. The relationship between donor TNFalpha - 308 (G/A) genotype and recipient acute GVHD in allo-BMT. Zhonghua Xue Ye Xue Za Zhi. 2002;23:397–399
  24. Wang JB, Ren HY, Li D, et al. Frequency of donor TNF-alpha gene polymorphism in patients with graft versus host disease following hematopoietic stem cell transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2002;10:133–137
  25. Rocha V, Franco RF, Porcher R, et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002;100:3908–3918
  26. Cavet J, Middleton PG, Segall M, et al. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood. 1999;94:3941–3946
  27. Shaw BE, Maldonado H, Madrigal JA, et al. Polymorphisms in the TNFA gene promoter region show evidence of strong linkage disequilibrium with HLA and are associated with delayed neutrophil engraftment in unrelated donor hematopoietic stem cell transplantation. Tissue Antigens. 2004;63:401–411
  28. Nedospasov SA, Udalova IA, Kuprash DV, et al. DNA sequence polymorphism at the human tumor necrosis factor (TNF) locus. Numerous TNF/lymphotoxin alleles tagged by two closely linked microsatellites in the upstream region of the lymphotoxin (TNF-beta) gene. Journal of Immunology (Baltimore, Md.). 1991;147:1053–1059
  29. Holzinger I, de Baey A, Messer G, et al. Cloning and genomic characterization of LST1: a new gene in the human TNF region. Immunogenetics. 1995;42:315–322
  30. Udalova IA, Nedospasov SA, Webb GC, et al. Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics. 1993;16:180–186
  31. Turner DM, Grant SC, Lamb WR, et al. A genetic marker of high TNF-alpha production in heart transplant recipients. Transplantation. 1995;60:1113–1117
  32. Pociot F, Molvig J, Wogensen L, et al. A tumour necrosis factor beta gene polymorphism in relation to monokine secretion and insulin-dependent diabetes mellitus. Scandinavian Journal of Immunology. 1991;33:37–49
  33. Keen LJ, DeFor TE, Bidwell JL, et al. Interleukin-10 and tumor necrosis factor alpha region haplotypes predict transplant-related mortality after unrelated donor stem cell transplantation. Blood. 2004;103:3599–3602
  34. Nordlander A, Uzunel M, Mattsson J, et al. The TNFd4 allele is correlated to moderate-to-severe acute graft-versus-host disease after allogeneic stem cell transplantation. British Journal of Haematology. 2002;119:1133–1136
  35. Bettens F, Passweg J, Gratwohl A, et al. Association of TNFd and IL-10 polymorphisms with mortality in unrelated hematopoietic stem cell transplantation. Transplantation. 2006;81:1261–1267
  36. Ishikawa Y, Kashiwase K, Akaza T, et al. Polymorphisms in TNFA and TNFR2 affect outcome of unrelated bone marrow transplantation. Bone Marrow Transplantation. 2002;29:569–575
  37. Bogunia-Kubik K, Lange A. HSP70-hom gene polymorphism in allogeneic hematopoietic stem-cell transplant recipients correlates with the development of acute graft-versus-host disease. Transplantation. 2005;79:815–820
  38. Stark GL, Dickinson AM, Jackson GH, et al. Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation. Transplantation. 2003;76:1742–1749
  39. Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. European Journal of Immunogenetics. 1997;24:1–8
  40. Edwards-Smith CJ, Jonsson JR, Purdie DM, et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology. 1999;30:526–530
  41. Morita C, Horiuchi T, Tsukamoto H, et al. Association of tumor necrosis factor receptor type II polymorphism 196R with Systemic lupus erythematosus in the Japanese: molecular and functional analysis. Arthritis and Rheumatism. 2001;44:2819–2827
  42. Cavet J, Dickinson AM, Norden J, et al. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood. 2001;98:1594–1600
  43. Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. The New England Journal of Medicine. 2003;349:2201–2210
  44. Socie G, Loiseau P, Tamouza R, et al. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation. 2001;72:699–706
  45. Kim DH, Lee NY, Sohn SK, et al. IL-10 promoter gene polymorphism associated with the occurrence of chronic GVHD and its clinical course during systemic immunosuppressive treatment for chronic GVHD after allogeneic peripheral blood stem cell transplantation. Transplantation. 2005;79:1615–1622
  46. Seo KW, Kim DH, Sohn SK, et al. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplantation. 2005;36:1089–1095
  47. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. The Journal of Biological Chemistry. 2000;275:18138–18144
  48. Karabon L, Wysoczanska B, Bogunia-Kubik K, et al. IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease. Human Immunology. 2005;66:700–710
  49. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. The Journal of Clinical Investigation. 1998;102:1369–1376
  50. Mlynarczewska A, Wysoczanska B, Karabon L, et al. Lack of IFN-gamma 2/2 homozygous genotype independently of recipient age and intensity of conditioning regimen influences the risk of aGVHD manifestation after HLA-matched sibling haematopoietic stem cell transplantation. Bone Marrow Transplantation. 2004;34:339–344
  51. Bogunia-Kubik K, Mlynarczewska A, Wysoczanska B, et al. Recipient interferon-gamma 3/3 genotype contributes to the development of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2005;90:425–426
  52. Bogunia-Kubik K, Mlynarczewska A, Jaskula E, et al. The presence of IFNG 3/3 genotype in the recipient associates with increased risk for Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology. 2006;132:326–332
  53. Cullup H, Stark G. Interleukin-1 polymorphisms and graft-vs-host disease. Leukemia & Lymphoma. 2005;46:517–523
  54. Cullup H, Dickinson AM, Cavet J, et al. Polymorphisms of interleukin-1alpha constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation. British Journal of Haematology. 2003;122:778–787
  55. MacMillan ML, Radloff GA, DeFor TE, et al. Interleukin-1 genotype and outcome of unrelated donor bone marrow transplantation. British Journal of Haematology. 2003;121:597–604
  56. Grainger DJ, Heathcote K, Chiano M, et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Human Molecular Genetics. 1999;8:93–97
  57. Leffell MS, Vogelsang GB, Lucas DP, et al. Association between TGF-beta expression and severe GVHD in allogeneic bone marrow transplantation. Transplantation Proceedings. 2001;33:485–486
  58. Hattori H, Matsuzaki A, Suminoe A, et al. Polymorphisms of transforming growth factor-beta1 and transforming growth factor-beta1 type II receptor genes are associated with acute graft-versus-host disease in children with HLA-matched sibling bone marrow transplantation. Bone Marrow Transplantation. 2002;30:665–671
  59. Banovic T, MacDonald KP, Morris ES, et al. TGF-beta in allogeneic stem cell transplantation: friend or foe?. Blood. 2005;106:2206–2214
  60. Mullighan CG, Heatley S, Doherty K, et al. Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood. 2002;99:3524–3529
  61. van der Straaten HM, Fijnheer R, Nieuwenhuis HK, et al. The FcgammaRIIa-polymorphic site as a potential target for acute graft-versus-host disease in allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2005;11:206–212
  62. Cavanagh G, Chapman CE, Carter V, et al. Donor CD31 genotype impacts on transplant complications after human leukocyte antigen-matched sibling allogeneic bone marrow transplantation. Transplantation. 2005;79:602–605
  63. Behar E, Chao NJ, Hiraki DD, et al. Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. The New England Journal of Medicine. 1996;334:286–291
  64. Nichols WC, Antin JH, Lunetta KL, et al. Polymorphism of adhesion molecule CD31 is not a significant risk factor for graft-versus-host disease. Blood. 1996;88:4429–4434
  65. Holler E, Rogler G, Herfarth H, et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood. 2004;104:889–894
  66. Holler E, Rogler G, Brenmoehl J, et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood. 2006;107:4189–4193
  67. Granell M, Urbano-Ispizua A, Arostegui JI, et al. Detrimental effect of NOD2/CARD15 polymorphisms in T-cell depleted allogeneic stem cell transplantation. Bone Marrow Transplantation. 2006;37(S79):P431
  68. Middleton PG, Cullup H, Dickinson AM, et al. Vitamin D receptor gene polymorphism associates with graft-versus-host disease and survival in HLA-matched sibling allogeneic bone marrow transplantation. Bone Marrow Transplantation. 2002;30:223–228
  69. Middleton PG, Norden J, Cullup H, et al. Oestrogen receptor alpha gene polymorphism associates with occurrence of graft-versus-host disease and reduced survival in HLA-matched sib-allo BMT. Bone Marrow Transplantation. 2003;32:41–47
  70. Mullighan C, Heatley S, Doherty K, et al. Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation. Transplantation. 2004;77:587–596
  71. Shamim Z, Ryder LP, Heilmann C, et al. Genetic polymorphisms in the genes encoding human interleukin-7 receptor-alpha: prognostic significance in allogeneic stem cell transplantation. Bone Marrow Transplantation. 2006;37:485–491
  72. Micallef MJ, Ohtsuki T, Kohno K, et al. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. European Journal of Immunology. 1996;26:1647–1651
  73. Tominaga K, Yoshimoto T, Torigoe K, et al. IL-12 synergizes with IL-18 or IL-1beta for IFN-gamma production from human T cells. International Immunology. 2000;12:151–160
  74. Cardoso SM, DeFor TE, Tilley LA, et al. Patient interleukin-18 GCG haplotype associates with improved survival and decreased transplant-related mortality after unrelated-donor bone marrow transplantation. British Journal of Haematology. 2004;126:704–710
  75. Ulrich CM, Yasui Y, Storb R, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood. 2001;98:231–234
  76. Kim I, Lee K-H, Kim JH et al. Polymorphisms of the methylenetetrahydrofolate reductase gene and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Annals of Hematology [in press].
  77. Murphy N, Diviney M, Szer J, et al. Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate. Bone Marrow Transplantation. 2006;37:773–779
  78. Rocha V, Porcher R, Filion A, et al. Association of Pharmacogenes polymorphisms with toxicities and GvHD after HLA-identical sibling bone marrow transplantation. Blood. 2003;102:241a;(abstract 848)
  79. Hesselink DA, van Gelder T, van Schaik RH. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?. Pharmacogenomics. 2005;6:323–337
  80. Oh H, Loberiza FR, Zhang MJ, et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2005;105:1408–1416
  81. Kubistova Z, Mrazek F, Tudos Z, et al. Distribution of 22 cytokine gene polymorphisms in the healthy Czech population. International Journal of Immunogenetics. 2006;33:261–267
  82. Laguila Visentainer JE, Lieber SR, Lopes Persoli LB, et al. Relationship between cytokine gene polymorphisms and graft-versus-host disease after allogeneic stem cell transplantation in a Brazilian population. Cytokine. 2005;32:171–177
  83. Hoffmann SC, Stanley EM, Darrin Cox E, et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation. 2001;72:1444–1450
  84. MacMillan ML, Radloff GA, Kiffmeyer WR, et al. High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation. Transplantation. 2003;76:1758–1762
  85. Kogler G, Middleton PG, Wilke M, et al. Recipient cytokine genotypes for TNF-alpha and IL-10 and the minor histocompatibility antigens HY and CD31 codon 125 are not associated with occurrence or severity of acute GVHD in unrelated cord blood transplantation: a retrospective analysis. Transplantation. 2002;74:1167–1175
  86. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet. 2003;361:865–872
  87. Ollier WE. Cytokine genes and disease susceptibility. Cytokine. 2004;28:174–178
  88. Weisdorf D, Hakke R, Blazar B, et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation. 1991;51:1197–1203
  89. Niederwieser D, Pepe M, Storb R, et al. Factors predicting chronic graft-versus-host disease and survival after marrow transplantation for aplastic anemia. Bone Marrow Transplantation. 1989;4:151–156
  90. Clave E, Rocha V, Talvensaari K, et al. Prognostic value of pretransplantation host thymic function in HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2005;105:2608–2613
  91. Talvensaari K, Clave E, Douay C, et al. A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation. Blood. 2002;99:1458–1464
  92. Leisenring WM, Martin PJ, Petersdorf EW, et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood. 2006;108:749–755
  93. Dickinson AM. Biobanks and registries for HSCT research: potential for future individualized medicine. International Journal of Immunogenetics. 2006;33:153–154

PII: S1521-6926(06)00073-9

doi: 10.1016/j.beha.2006.10.004

Best Practice & Research Clinical Haematology
Volume 20, Issue 2 , Pages 189-207 , June 2007

Article Tools

* Image Usage & Resolution